Trained as a physician and immunologist/virologist in Berlin, Boston, Paris and La Jolla, Dr. Homann has a long-standing interest in autoimmune and infectious disease, in particular the generation, maintenance, modulation, pathogenic potential and protective capacity of specific T cell immunity. Dr. Homann began his work as an independent investigator at the University of Colorado, joined the faculty at Mount Sinai in 2014, and was promoted to full Professor with tenure in 2019. Active areas of preclinical investigation include T cell memory; the role of various accessory pathways (chemokines, CD4+T cell help, SLAM family receptors, adenosine, complement system) in regulation of CD8+T cell responses to acute and chronic viral infections; and the concurrent therapeutic modulation of immune responses and beta cell survival in type 1 diabetes (T1D). The overarching goal of these endeavors is the development, adaptation and optimization of therapeutic strategies that effectively curtail (autoimmunity) or embellish (infectious disease) T cell responses with prophylactic and/or curative intent. Over the past decade, Dr. Homann has expanded his research program to encompass a broader context of pancreatic islet cell biology and histopathology in human T1D, and he has launched multiple collaborative efforts to better leverage complementary expert knowledge, unique technology access and more effective overall implementation of research strategies.
Multi-Disciplinary Training Areas
Immunology [IMM], Microbiology [MIC]Education
MD, Freie Universitat
MA, Hochschule der Kunste
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Homann did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.